Expect to See More Admitted Patients Taking Empagliflozin or Liraglutide at Home

New evidence will raise questions about cardiovascular benefits of type 2 diabetes meds.

Diabetes meds are commonly picked based on their A1C lowering, side effects, cost, etc. But now CV impact will also be important.

In fact, the SGLT2 inhibitor empagliflozin (Jardiance) is poised to become the first diabetes med approved for reducing CV death in patients with type 2 diabetes and CV disease. It prevents CV death in one in 45 patients over 3 years...and overall mortality in one in 39 patients.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals